Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | GABRP | O00591 | 1/20 | 0.40 |
| ▸ | GABRD | O14764 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.40 |
| ▸ | GABRE | P78334 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.40 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.40 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.40 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.40 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25635425 | 1.00 | TSHR (0.40) | TSHRGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL1073547 | 0.94 | TSHR (0.40) | TSHRGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL11470248 | 0.92 | TSHR (0.39) | TSHRGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL14839455 | 0.92 | TSHR (0.43) | TSHRGABRPGABRDGABRA1GABRB1 | |
| Hydrochloric Acid SCHEMBL11473356 | 0.90 | TSHR (0.37) | TSHRGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL18850146 | 0.90 | ANPEP (0.42) | TSHRGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL11540012 | 0.88 | TSHR (0.43) | TSHRGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL11485631 | 0.88 | TSHR (0.43) | TSHRGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL11485634 | 0.88 | TSHR (0.43) | TSHRGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL30259963 | 0.87 | GRM2 (0.36) | TSHRGABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12297226-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-20240317790-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2024-09-26 | — | — | US | disclosed |
| EP-4424372-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | Gilead Sciences, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-4204421-B1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES INC (US) | 2024-05-15 | — | — | EP | disclosed |
| US-11926645-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| US-11814406-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814406-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814406-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| CN-116568688-A | Compounds and methods for treating viral infections | 吉利德科学公司 | 2023-08-08 | — | — | CN | disclosed |
| EP-4204421-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20230151043-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230151043-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230151043-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20220081462-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2022-03-17 | — | — | US | disclosed |
| US-20220081462-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220081462-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, ACE | TSHR 4452/4885GABRP 3596/4885GABRD 3990/4885 |
| US-11814406-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, ACE | TSHR 4452/4885GABRP 3596/4885GABRD 3990/4885 |
| US-12297226-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, ACE | TSHR 4452/4885GABRP 3596/4885GABRD 3990/4885 |
| US-20230151043-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, ACE | TSHR 4452/4885GABRP 3596/4885GABRD 3990/4885 |
| US-20240317790-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, ACE | TSHR 4452/4885GABRP 3596/4885GABRD 3990/4885 |
| US-11926645-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, ACE | TSHR 4452/4885GABRP 3596/4885GABRD 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.